Interaksi Glukagon

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Acute Pancreatitis Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists, including BYETTA [see Adverse Reactions (6.2) ] . (label Eksenatid, Peringatan dan perhatian)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (label Glukagon, Interaksi obat)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (label Glukagon, Interaksi obat)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (label Glukagon, Interaksi obat)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (label Glukagon, Interaksi obat)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (label Glukagon, Interaksi obat)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (label Glukagon, Interaksi obat)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (label Glukagon, Interaksi obat)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (label Glukagon, Interaksi obat)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (label Glukagon, Interaksi obat)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (label Glukagon, Interaksi obat)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (label Glukagon, Interaksi obat)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (label Glukagon, Interaksi obat)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (label Glukagon, Interaksi obat)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (label Glukagon, Interaksi obat)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (label Glukagon, Interaksi obat)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (label Glukagon, Interaksi obat)

If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure. (label Glukagon, Peringatan dan perhatian)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (label Glukagon, Interaksi obat)

The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics,… (label Glimepirid, Interaksi obat)

…glucose-lowering effect of GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (label Glipizid, Interaksi obat)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (label Glukagon, Interaksi obat)

Indomethacin Clincial Impact: In patients taking indomethacin, GVOKE may lose its ability to raise blood glucose or may even produce hypoglycemia. (label Glukagon, Interaksi obat)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (label Glukagon, Peringatan dan perhatian)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (label Glukagon, Peringatan dan perhatian)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (label Glukagon, Peringatan dan perhatian)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (label Glukagon, Peringatan dan perhatian)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (label Glukagon, Peringatan dan perhatian)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (label Glukagon, Peringatan dan perhatian)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (label Glukagon, Interaksi obat)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (label Glukagon, Interaksi obat)

Hyperglycemia and Hypoglycemia Pharmacological studies in animals and humans show that lanreotide, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon. (label Lanreotid, Peringatan dan perhatian)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (label Glukagon, Interaksi obat)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (label Glukagon, Interaksi obat)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (label Glukagon, Interaksi obat)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (label Glukagon, Interaksi obat)

Hyperglycemia and Hypoglycemia MYCAPSSA alters the balance between the counter-regulatory hormones, insulin, glucagon, and growth hormone, which may result in hypoglycemia, or hyperglycemia, or diabetes mellitus. (label Oktreotid, Peringatan dan perhatian)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (label Glukagon, Interaksi obat)

The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics,… (label Pioglitazon dan glimepirid, Interaksi obat)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (label Glukagon, Interaksi obat)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (label Glukagon, Interaksi obat)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (label Glukagon, Interaksi obat)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (label Glukagon, Interaksi obat)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (label Glukagon, Peringatan dan perhatian)

Intervention Monitor patients for unusual bruising or bleeding, as adjustments in warfarin dosage may be required. (label Glukagon, Interaksi obat)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

Glucagon-like peptide-1 (GLP-1) receptor agonists have induced thyroid C-cell adenomas and carcinomas in mice and rats at clinically relevant exposures. (label Dulaglutid, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and… (label Repaglinid, Interaksi obat)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)